Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression of insulin-like growth factor 1 (IGF-1), compared to monthly Sandostatin LAR® in healthy volunteers – interim results

Presented at ENEA 2022 – 20th Congress of the European NeuroEndocrine Association

A.Bellona , J.Kleinb , D.Spaggiaria , M.Marquardta , F. Frérartc , D. Rechavi-Robinsona , A. Marguerettazd , B. Plagèsd , L.Merinata , C. Bedena , B. Ducreya , B.Gavilleta , L.Tauchmanovaa

a Debiopharm, Lausanne, SWITERLAND
b SGS Belgium – Health & Nutrision, Edegem, BELGIUM
c SGS Belgium – Health & Nutrision, Mechelen, BELGIUM
d Debiopharm Research & Manufacturing, Martigny, SWITERLAND


Debio 4126-101 trial is an open-label, active-controlled, parallel-group, single site Phase 1 study in healthy volunteers with flexible design. The aim is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety and tolerability of a single administration IM or SC of two formulations in two solvents of a 3-month sustained-release octreotide formulation, Debio 4126.​